A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs LNA 043 (Primary)
- Indications Cartilage disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 21 Nov 2018 Planned End Date changed from 11 Dec 2018 to 16 Sep 2019.
- 21 Nov 2018 Planned primary completion date changed from 11 Dec 2018 to 16 Sep 2019.
- 12 Mar 2018 Planned End Date changed from 28 Sep 2018 to 11 Dec 2018.